Compare HKIT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HKIT | NEUP |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | China | United States |
| Employees | N/A | 8 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 23.0M |
| IPO Year | 2018 | N/A |
| Metric | HKIT | NEUP |
|---|---|---|
| Price | $1.06 | $4.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 71.4K | 57.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $3.65 |
| 52 Week High | $4.21 | $21.31 |
| Indicator | HKIT | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 60.87 |
| Support Level | $0.53 | $3.92 |
| Resistance Level | $1.44 | $5.06 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 36.35 | 70.35 |
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.